TVTX - Travere Therapeutics, Inc. Stock Price, Fair Value and News

$34.82+0.83 (+2.44%)

Market Closed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

TVTX Price Action

Last 7 days

-4.0%

Last 30 days

0.8%

Last 90 days

64.6%

Trailing 12 Months

79.7%

TVTX RSI Chart

TVTX Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-35.19

Price/Sales (Trailing)

7.15

EV/EBITDA

-97.95

Price/Free Cashflow

-42.75

TVTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

TVTX Fundamentals

TVTX Revenue

Revenue (TTM)

435.8M

Rev. Growth (Yr)

162.11%

Rev. Growth (Qtr)

44.05%

TVTX Earnings

Earnings (TTM)

-88.5M

Earnings Growth (Yr)

146.9%

Earnings Growth (Qtr)

301.54%

TVTX Profitability

EBT Margin

-20.32%

Return on Equity

-120.36%

Return on Assets

-16.44%

Free Cashflow Yield

-2.34%

TVTX Investor Care

Shares Dilution (1Y)

14.63%

Diluted EPS (TTM)

-1.04

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2025	273.5M	333.9M	435.8M	0
2024	155.7M	177.6M	203.4M	233.2M
2023	116.9M	120.5M	129.5M	145.2M
2022	126.2M	120.6M	115.1M	109.5M
2021	198.0M	204.1M	221.2M	131.8M
2020	183.5M	187.3M	194.0M	198.3M
2019	165.4M	168.8M	172.4M	175.3M
2018	159.7M	162.3M	162.7M	164.2M
2017	138.2M	143.7M	150.1M	154.9M
2016	111.5M	120.8M	126.7M	133.6M
2015	45.5M	63.9M	83.5M	99.9M
2014	7.3M	14.3M	21.2M	28.2M
2013	6.8M	4.7M	2.5M	360.0K
2012	0	0	0	9.0M
2011	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About Travere Therapeutics, Inc.

Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of homozygous cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; and TVT-058, a novel investigational human enzyme replacement candidate, which is in Phase I/II clinical trials for the treatment of classical homocystinuria. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences and patient advocacy organizations, CDG Care, and Alagille Syndrome Alliance for the identification of potential small molecule therapeutics for Alagille syndrome. The company was formerly known as Retrophin, Inc. and changed its name to Travere Therapeutics, Inc. in November 2020. Travere Therapeutics, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

CEO	Dr. Eric M. Dube Ph.D.
WEBSITE	travere.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	462

Travere Therapeutics, Inc. Frequently Asked Questions

What is the ticker symbol for Travere Therapeutics, Inc.? What does TVTX stand for in stocks?

TVTX is the stock ticker symbol of Travere Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Travere Therapeutics, Inc. (TVTX)?

As of Wed Dec 03 2025, market cap of Travere Therapeutics, Inc. is 3.12 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TVTX stock?

You can check TVTX's fair value in chart for subscribers.

Is Travere Therapeutics, Inc. a good stock to buy?

The fair value guage provides a quick view whether TVTX is over valued or under valued. Whether Travere Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Travere Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TVTX.

What is Travere Therapeutics, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 03 2025, TVTX's PE ratio (Price to Earnings) is -35.19 and Price to Sales (PS) ratio is 7.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TVTX PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Travere Therapeutics, Inc.'s stock?

In the past 10 years, Travere Therapeutics, Inc. has provided 0.048 (multiply by 100 for percentage) rate of return.